Morbidity and Mortality Weekly Report

Completion of the Second Tranche of Stellantis Share Buyback Program and Weekly Report (September 1-7, 2023)

Retrieved on: 
Friday, September 8, 2023
Morbidity and Mortality Weekly Report, Rare-earth element

Completion of the Second Tranche of Stellantis Share Buyback Program and Weekly Report (September 1-7, 2023)

Key Points: 
  • Completion of the Second Tranche of Stellantis Share Buyback Program and Weekly Report (September 1-7, 2023)
    AMSTERDAM, September 8, 2023 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that its Second Tranche of the Share Buyback Program announced on June 7, 2023, covering up to €500 million to be executed in the open market during the period between June 7, 2023 and September 7, 2023, has been completed.
  • Since June 7, 2023 up to and including September 7, 2023, the Company has purchased a total of 30,660,186 common shares for a total consideration of €499,999,499.
  • During the period between September 1 up to and including September 7, 2023 the Company has repurchased the following common shares:

Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

Retrieved on: 
Thursday, August 3, 2023
ACIP, U.S. Department of Defense Strategy for Operating in Cyberspace, Parent, Office of Inspector General, U.S. Department of Health and Human Services, Vaccines for Children Program, Morbidity and Mortality Weekly Report, CDC, Child, Committee, Vaccination, The Committee, VFC, RSV, Patient, Risk, MMWR, Ageing, Disease, FDA, Immunization, Vaccine, Adolescence, Sanofi, Nirsevimab

The Committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.

Key Points: 
  • The Committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.
  • Additionally, the ACIP voted unanimously 11 to 0 to include Beyfortus in the Vaccines for Children (VFC) program.
  • “Today, we have turned the corner on the threat of RSV to our youngest, most vulnerable population.
  • Once approved, routine use of Beyfortus would be included in the CDC’s Child and Adolescent Immunization Schedule.

Vaccination in pregnancy greatly reduces risk of severe illness and death from COVID-19, and protects babies up to 6 months after birth

Retrieved on: 
Monday, July 3, 2023
Vaccine, Infection, Pregnancy, Placenta, Life, Stillbirth, Vaccination, SARS-CoV-2, Fetus, Safety, COVID-19, World, Morbidity and Mortality Weekly Report, Maternal death, Antibody, Delta, Messenger, Intensive care medicine, Mother, CDC, Public health, Patient, Population, Risk, MMWR, Blood, Korea Disease Control and Prevention Agency, Pre-eclampsia, Miscarriage, Internal bleeding, Mortality, Infant, ICU, Ageing, Disease, Center, Health, Death, World Health Organization, Apgar, Dietary supplement, Birth control, Omicron

From the early days of the pandemic, it has been evident that a COVID-19 infection in pregnancy can be serious.

Key Points: 
  • From the early days of the pandemic, it has been evident that a COVID-19 infection in pregnancy can be serious.
  • The data is stark: there is a five times higher risk of ICU admission and 22 times higher risk of maternal mortality due to COVID-19 infections in pregnancy.

Safety of COVID-19 vaccines in pregnancy

    • Despite the overwhelming data on the risks of COVID-19 infection in pregnancy, many have still been reluctant to get vaccinated, citing safety concerns.
    • We now have extensive evidence that shows COVID-19 vaccinations in pregnancy are safe, when given at any time during the pregnancy.

Infants protected by transfer of antibodies across placenta

    • Recent studies have shown that these IgG antibodies transferred to the fetus can remain in the baby for several months after birth.
    • One study showed 57 per cent of infants born to vaccinated mothers had detectable antibodies at six months.
    • Children younger than six months have the highest risk for severe outcomes associated with COVID-19 infections, including hospitalizations and death.

Benefits of a COVID-19 booster in pregnancy

    • Recently the World Health Organization recommended a COVID-19 booster during pregnancy if the last dose was over six months ago.
    • It is abundantly clear that COVID-19 infection in pregnancy carries considerable risk to the pregnant person and the fetus.

US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

Retrieved on: 
Thursday, June 22, 2023
Research, Infectious Diseases, FDA, Seniors, Biotechnology, Health, Consumer, Pharmaceutical, Science, ACIP, GSK, The New England Journal of Medicine, US Foods, Respiratory syncytial virus vaccine, Diabetes, Vaccination, United States Department of Health and Human Services, Season, Chronic lung disease, DSM-IV codes, Multimedia, Morbidity and Mortality Weekly Report, CDC, Death, GSK plc, RSV, State, Patient, Risk, MMWR, Stockholm Environment Institute US Center, Kidney, Ageing, Disease, III, Food, Vaccine, Poultry farming

GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.
  • Shared clinical decision making empowers patients in consultation with their healthcare providers to determine whether RSV vaccination is appropriate for them.
  • These data will be submitted to the US Food and Drug Administration (FDA) for review.
  • The ACIP recommendations will be forwarded to the director of the CDC and the US Department of Health and Human Services for review and approval.

Completion of the First Tranche of Stellantis Share Buyback Program and Weekly Report (May 12 – May 17, 2023)

Retrieved on: 
Thursday, May 18, 2023
Morbidity and Mortality Weekly Report, Rare-earth element

Completion of the First Tranche of Stellantis Share Buyback Program and Weekly Report (May 12 – May 17, 2023)

Key Points: 
  • Completion of the First Tranche of Stellantis Share Buyback Program and Weekly Report (May 12 – May 17, 2023)
    AMSTERDAM, May 18, 2023 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that its First Tranche of the Share Buyback Program announced on March 16, 2023, covering up to €500 million to be executed in the open market during the period between March 17, 2023 and June 19, 2023, has been completed.
  • Since March 17, 2023 up to and including May 17, 2023, the Company has purchased a total of 33,249,812 common shares for a total consideration of € 499,988,202.
  • During the period between May 12 up to and including May 17, 2023 the Company has repurchased the following common shares:

Autism Learning Partners Launches Center-Based ABA Therapy for Individuals in Lincoln, Rhode Island

Retrieved on: 
Thursday, April 13, 2023
ABA, Learning, Communication, Speech, Spectrum, ALP, LINCOLN, BCBA, Morbidity and Mortality Weekly Report, LABA, Applied behavior analysis, Language, Disability studies, CDC, School, Behavior, ASD, MMWR, M.A, Diagnosis, Mobility, Hospital Insurance and Diagnostic Services Act, Residential care

LINCOLN, R.I., April 13, 2023 /PRNewswire-PRWeb/ -- Autism Learning Partners (ALP), a national leader that specializes in the treatment of autism and other developmental disabilities, is pleased to announce its in-state expansion with the addition of our first ABA therapy center in Lincoln, Rhode Island. ALP initiated this center-based extension in the greater Providence area in response to the need for quality center-based services. Services support families living in Bristol, Kent, Newport, Providence, and Washington County. ALP is committed to continuing collaborative efforts with schools, ancillary services and medical providers in the greater Providence area and steadfast in its dedication to providing resources to families.

Key Points: 
  • Autism Learning Partners (ALP), a national leader that specializes in the treatment of autism and other developmental disabilities, is pleased to announce its in-state expansion with the addition of our first ABA therapy center in Lincoln, Rhode Island.
  • ALP initiated this center-based extension in the greater Providence area in response to the need for quality center-based services.
  • LINCOLN, R.I., April 13, 2023 /PRNewswire-PRWeb/ -- Autism Learning Partners (ALP), a national leader that specializes in the treatment of autism and other developmental disabilities, is pleased to announce its in-state expansion with the addition of our first ABA therapy center in Lincoln, Rhode Island.
  • To learn more about Autism Learning Partners and its services, please visit http://www.AutismLearningPartners.com .

Jason Foundation Highlights Rise in Suicide Rates and Behavior Among Youth

Retrieved on: 
Monday, February 13, 2023
Disease, Suicide, Life, Social Problems, Disability, Korea Disease Control and Prevention Agency, Suicidal ideation, Thought, 988 Suicide & Crisis Lifeline, Depression, Parent, CDC, Death, Morbidity and Mortality Weekly Report, Multimedia, Prevalence, Overalls, Mental health, Life insurance, Birth control

HENDERSONVILLE, Tenn., Feb. 13, 2023 /PRNewswire/ -- The Jason Foundation, Inc ., a nationally recognized leader in suicide prevention and awareness, shared data today released by the Centers for Disease Control and Prevention (CDC) that show an increase in suicide rates, deaths, and suicidal behavior in our nation's youth.

Key Points: 
  • HENDERSONVILLE, Tenn., Feb. 13, 2023 /PRNewswire/ -- The Jason Foundation, Inc ., a nationally recognized leader in suicide prevention and awareness, shared data today released by the Centers for Disease Control and Prevention (CDC) that show an increase in suicide rates, deaths, and suicidal behavior in our nation's youth.
  • Last week, the CDC released a preliminary report regarding changes in suicide rates examined by race, ethnicity, and age.
  • In 2021, suicide was the second leading cause of death for middle and high school-aged youth (12 – 18).
  • The Jason Foundation is dedicated to the awareness and prevention of youth suicide through educational programs that equip youth, parents, educators, and the community with the resources to identify and assist at-risk youth.

Playing Catch-Up: Hospitals Seek High-Tech Solutions to Meet Telehealth Demands

Retrieved on: 
Monday, October 24, 2022
Acumen, National Association Medical Staff Services, Morbidity and Mortality Weekly Report, Use, Digital technology, Communication, Sale, ICU, Life, Hospital, Bed, Cardiology, Patient, MMWR, MOME, Telehealth, Technology, Radiology, Telemetry, Disease, Economics, Decision-making, ARC, Vital signs, FDA, COVID-19, Medical device

WALTHAM, Mass., Oct. 24, 2022 /PRNewswire-PRWeb/ -- In 2020, the COVID-19 pandemic dramatically changed hospital operations. As facilities limited non-COVID care, medical providers turned to telehealth solutions to treat patients.(1) Patients and providers relied on a patchwork of videoconferencing systems, patient portals, and rudimentary home health equipment to manage non-emergency care. "Value-based care means flexibility in clinical capability," says The Virtual Telemetry Company, InfoBionic, CEO Stuart Long. "Portable telemetry for on-site use and remote telemetry for home use are the logical next steps in this era of virtual care. Telehealth is only growing in popularity and effectiveness. Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology."

Key Points: 
  • Hospitals, providers, and patients all understand the need for high-tech, reliable monitoring that can go from hospital to home without compromising care.
  • As facilities limited non-COVID care, medical providers turned to telehealth solutions to treat patients.
  • Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology."
  • Providers and healthcare facilities are racing to upgrade systems to use telehealth more effectively in the near future.

New Survey Shows Over 2.5 Million Kids Used E-Cigarettes in 2022 and Most Use Flavored Products that the FDA Must Take Off the Market Without Further Delay

Retrieved on: 
Friday, October 7, 2022
CDC, Congress, Sale, Risk, City, Fruit, Review, Policy, COVID-19, Multimedia, Morbidity and Mortality Weekly Report, Marketing, Disease, Menthol, Smokeless tobacco, FDA, Tobacco

WASHINGTON, Oct. 6, 2022 /PRNewswire/ -- The results of the 2022 National Youth Tobacco Survey released today show that youth e-cigarette use remains an urgent public health problem in the United States, and it continues to be driven by the widespread availability of flavored products that the FDA should have removed from the market by now. The survey shows that 2.55 million middle and high school students reported current (past 30-day) e-cigarette use in 2022, including 14.1% of high school students and 3.3% of middle school students. 85% of youth e-cigarette users reported using flavored products, with fruit, candy/desserts/other sweets, mint and menthol reported as the most popular flavors.

Key Points: 
  • 85% of youth e-cigarette users reported using flavored products, with fruit, candy/desserts/other sweets, mint and menthol reported as the most popular flavors.
  • It is unacceptable that over 2.5 million kids still use e-cigarettes when there is a clear solution to the problem: Eliminate all flavored e-cigarettes.
  • The FDA has the power to do so, but it has repeatedly failed to act and left our nation's kids at risk.
  • In one of its most startling findings, the new survey indicates that kids are using a wider range of flavored e-cigarette brands.

New Data Show More Than 2.5 Million U.S. Youth Currently Use E-Cigarettes

Retrieved on: 
Thursday, October 6, 2022
MDO, Head, CDC, Congress, Seizure, Marketing, Sale, Morbidity and Mortality Weekly Report, Risk, LLC, Regulation of tobacco by the U.S. Food and Drug Administration, Center for Tobacco Products, Student, Food, Center, Smokeless tobacco, Nicotine, Adult, Puff, Letter, Federal Food, Drug, and Cosmetic Act, Korea Disease Control and Prevention Agency, NTN, FDA, COVID-19, Compliance, Public health, Bottled water, Tobacco, Dietary supplement, Vuse

SILVER SPRING, Md., Oct. 6, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration, in coordination with the Centers for Disease Control and Prevention (CDC), released federal data from the 2022 National Youth Tobacco Survey (NYTS) on e-cigarette use among U.S. youth. The findings, published in Morbidity & Mortality Weekly Report, show that youth use of e-cigarettes remains high, with 2.5 million (9.4%) of the nation's middle and high school students reporting current e-cigarette use.

Key Points: 
  • The FDA remains steadfast in its commitment to using the full range of our authorities to address youth e-cigarette use head-on."
  • Among these youth e-cigarette users, nearly 85% reported using flavored e-cigarettes, and more than 1 in 4 (27.6%) reported daily use of an e-cigarette.
  • The top three brands that current youth e-cigarette users reported "usually" using were Puff Bar (14.5%), Vuse (12.5%), and Hyde (5.5%).
  • The steps FDA has taken today are a continuation of the FDA's efforts to address e-cigarettes that appeal to youth.